For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Aiming to Become Agile, Nimble Innovative Drug Firm: Mr Kannan of Allergan
July 22, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 22, 2002
- Press Seminar
July 15, 2002
- Healthcare Reform to Raise People's Burden by \1.5 Trillion: Korosho
July 15, 2002
- Takeda, J&J to Promote Tylenol for Use on Empty Stomach
July 15, 2002
- Outline for Intellectual Property Strategy Finalized
July 15, 2002
- Asahi Beer Pham Merges Its Drug and Food Subsidiaries
July 15, 2002
- REGULATORY NEWS IN BRIEF
July 15, 2002
- OTC NEWS IN BRIEF
July 15, 2002
- National Nagano Hospital to Encourage Use of Generics
July 15, 2002
- RDKK Aims at Sales of \60 Bil., 15% Share in 2006
July 15, 2002
- Monkasho Not Intending to Abolish Department of Pharmacy
July 15, 2002
- Takara Bio Reshuffles Its Business Structure
July 15, 2002
- GLs for Epidemiological Studies Enforced
July 15, 2002
- Dainippon to Boost Overseas Sales to 7% in FY2006: President Miyatake
July 15, 2002
- DIAGNOSTIC NEWS IN BRIEF
July 15, 2002
- Takeda Expects SCOPE Results to Boost Sales of Candesartan
July 15, 2002
- MEDICAL DEVICE NEWS IN BRIEF
July 15, 2002
- Tsumura Studying Combination of Western, Oriental Medicine
July 15, 2002
- PhRMA Adopts Principles for Conduct of Clinical Trials
July 15, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…